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quired for T1D to develop, therefore, bestows only risk,
the penetrance of this genotype being heavily depen-
dent on environmental factors and random develop-
mental factors (Figure 1).
These features are mirrored by animal models of T1D
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Cambridge CB2 2XY (Ikegami and Makino, 2001; Mordes et al., 1996; Serreze
and Leiter, 2001; Wicker et al., 1995), recapitulating theUnited Kingdom
dependence on environmental factors such as diet and
infection, and on alleles of multiple genes scattered
throughout the genome including a critical and majorSummary
role of the orthologs of the HLA class II genes, IA and
IE. One of the most studied, the NOD mouse, modelsPopulations of humans and mice contain alleles at
polyendocrine autoimmunity, with chronic inflammationmany loci that protect from immune-mediated dis-
of the pancreatic islets, the thyroid gland, and the sali-eases. Identification of these alleles, some which are
vary glands (modeling Sjo¨gren’s syndrome), to mentionlikely to function in immune recognition, tolerance,
only three. Inflammation, its initiation and pathogenicity,and regulation, will facilitate the development of diag-
is strongly dependent on MHC class II genotype as wellnostics as well as therapeutics that alter disease pro-
as a number of non-MHC genes across the genome.gression.
Identification of these genes and characterization of the
differential functions of their alleles, positively and nega-Human insulin-dependent or type 1 diabetes (T1D) be-
longs to a family of diseases characterized by their asso- tively associated with disease, will help us to understand
disease mechanisms and pathways, providing targetsciation with the HLA class II genes in the major histocom-
patibility complex (MHC) and the appearance of for disease prevention.
Although the emphasis in the study of the geneticantibodies against self-proteins (Bach, 1994; Merriman
et al., 2001; Tisch and McDevitt, 1996; Todd, 1999; Vyse basis of multifactorial disease is usually on susceptibility
to disease, it is the protection afforded by certain allelesand Todd, 1996). Histological analysis of autopsy (Pipel-
eers and Ling, 1992) and biopsy (Imagawa et al., 2001) that is the focus of this review. Disease susceptibility
can be viewed in part as lack of protection. Indeed,pancreas reveals immune infiltrates dominated by CD8
T cells. Multiple abnormalities in the T cell and antigen- it can be argued that the environment also contains
protective factors (Todd, 1991). Understanding the pro-presenting cell compartments have been observed.
Taken together, these basic and established observa- tective functions of alleles and attempts to restore or
enhance these effects in individuals lacking them shouldtions classify T1D as a disease of the immune system,
and in its interaction with the insulin-producing () cells contribute to future efforts to reduce the incidence of
T1D and other immune-mediated diseases.of the pancreas, as an inflammatory disease.
The mechanisms of disease pathogenesis remain ob-
scure, however, with multiple causes in the genetic HLA Class II Loci
background and in the environment beginning very early Certain alleles at the MHC HLA class II loci HLA-DQB1
in life, and probably with maternal influences (Figure 1; and -DRB1 provide very significant life-long protection
Gale and Gillespie, 2001; Harrison, 2001; Robles and from T1D, despite the presence of predisposing alleles
Eisenbarth, 2001; Yu et al., 2000; Ziegler et al., 1999). of the class II genes themselves and of other loci and
The disease has doubled in incidence since the 1940s environmental exposures that could trigger or precipi-
(Gardner et al., 1997). In first- and second-degree rela- tate the disease (Cucca et al., 2001). Several class II
tives of T1D cases, the frequency of Graves’ disease alleles or haplotypes are hardly ever transmitted from
(GD) and rheumatoid arthritis (RA) is increased (Merri- parents to T1D offspring. In population studies, geno-
man et al., 2001). The familial clustering of these dis- types that carry these haplotypes are significantly re-
eases, which are also characterized by irregular immune duced in the frequency of the cases compared to healthy
system activity and infiltrates of immune cells in the controls such as the DR2 (DR15)-DQB1*0602 haplotype,
target organs, the pancreatic islets, and the thyroid and which provides 97% protection. This effect is dominant.
the joints, respectively is due to the sharing of alleles The overall pattern of the relative predisposition of the
of disease genes by family members. These diseases numerous associated class II alleles and haplotypes in
are common, affecting at least 0.1% of populations, and T1D is two sided, from highly susceptible (certain DR3-
their inheritance does not follow a standard Mendelian DQ2 and DR4-DQ8 haplotypes) to highly protective
mode of inheritance (Vyse and Todd, 1996). Genetically (Cucca et al., 2001). This contrasts with other well-char-
identical monozygotic twins, one of whom has T1D, have acterized immune-associated diseases such as multiple
only a less than 50% risk of being concordant for disease sclerosis (MS) and celiac disease, for which significant
(Redondo et al., 2001). The combination of alleles re- dominantly protective associations with class II alleles
are absent. These data, along with strong, albeit not
perfect, correlations of certain class II amino acids and1 E-mail: john.todd@cimr.cam.ac.uk (J.A.T.), linda.wicker@cimr.cam.
ac.uk (L.S.W.) peptide binding pocket structures with susceptibility
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Figure 1. The Four-Dimensional Complexity of the Interaction of Genotype and Environment in Type 1 Diabetes
and resistance, particularly DQ 57 and pocket 9 (Cucca of life (Bonifacio et al., 1999; Yu et al., 2000). Since the
median age at onset of T1D is 12 years, there are clearlyet al., 2001; Lee et al., 2001), suggest that a particular
 cell antigen, such as preproinsulin (PPI), is involved often prolonged efforts by the resistance mechanisms
to halt  cell damage and disease. These pathways ofand that self-tolerance or nonresponsiveness to it, in
a diabetes-resistant individual, is subject to dominant resistance need to be identified, and then it can be
explored whether they can be modulated to delay ormechanisms of self-tolerance (Cucca et al., 2001). In
addition, as found for the DQ molecule in celiac disease prevent T1D in children who lack protective class II mol-
ecules. Perhaps if we knew the identity of the primary(Sollid, 2000), class II molecules are also involved in the
actual antigen presentation in the inflammation in the antigen, peptides from which drive class II-mediated
resistance (Cucca et al., 2001), we could harness thisislets and pancreatic lymph nodes (Lee et al., 2001).
Dominant tolerance, such as class II-mediated deletion safely and specifically to prevent diabetes. Recent clini-
cal trials, however, using an altered peptide ligand ap-of potentially autoreactive thymocytes (Schmidt et al.,
1997), production of T regulatory cells in the thymus proach to reduce the progression of multiple sclerosis,
emphasize the need for exquisite monitoring of the im-(Jordan et al., 2001), or epitope stealing could account
for part of the observed, but unique, class II-mediated mune response during treatment (Bielekova et al., 2000;
Kappos et al., 2000).dominant protection against T1D (Figure 2). The elucida-
tion of the association of HLA with T1D (designated
IDDM1), which may well involve conserved class II pep- Preproinsulin Gene
The second known locus (IDDM2) in T1D, a polymor-tide binding structure across species and a common 
cell target peptide structure, suggests a role for the phism in the promoter region of the PPI gene (INS) itself,
provides among the best evidence in humans that pep-thymus and its class II-mediated functions in resistance
to T1D (Cucca et al., 2001). tides from PPI are primary in disease etiology. The earli-
est antibodies against islets to appear in children andDominant protection by class II molecules in NOD
mice and in transgenic models is well established, with in mice are insulin autoantibodies (IAA) (Bonifacio et al.,
1999; Yu et al., 2000; Ziegler et al., 1999). IAA precedeat least two pathways of T cell tolerance or regulation
involved (Luhder et al., 1998), namely thymic deletion antibodies to GAD and to IA2. Currently, PPI is the fa-
vored primary antigen in T1D. This is consistent with(Schmidt et al., 1997) and the generation and action of
T regulatory cells (Jordan et al., 2001). It is noted that genetic data. A polymorphism at 596 bp 5 of the PPI
gene (INS on chromosome 11p15) has in Europeans twothe class II genes in the MHC do not explain all of the
association of the MHC region with T1D, in humans or in main size classes of alleles of a complex tandem repeat
of 14–15 oligonucleotides (the variable number of tan-the NOD mouse, with evidence for additional, nonclass II
loci within and flanking the MHC (Hattori et al., 1999; dem repeat, VNTR, locus). The larger VNTR class,
dubbed “III,” which is present at 30% frequency, pro-Ikegami et al., 1995).
As we will discuss below, naturally occurring genetic vides 70% protection against T1D over a lifetime regard-
less of which HLA susceptibility alleles an individualresistance acts at the initiation of insulitis and in the
regulation of the pathogenicity of the insulitis (Lyons et might have (Bennett and Todd, 1996). In epidemiological
terms, this is a massive effect. If only a fraction of thisal., 2000a, 2000b). In children, there is emerging evi-
dence that pivotal programming events leading to pro- protection could be mimicked pharmacologically, then
reduction of disease risk could be achieved. Combina-tection against T1D occur within the first 2 to 3 years
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Figure 2. A Model for the Interaction of the
Etiological Variants of the HLA Class II Genes
and the Preproinsulin Gene in Type 1 Dia-
betes
tions of protective alleles in NOD mouse “double” or therefore, reduced anti- cell inflammation and destruc-
tion (Figure 2). It is noted that expression of insulin and“triple” congenic strains are almost completely resistant
to T1D (see below). other antigens may not be restricted to immune cells
of the thymus, but is also observed in macrophages/As found for T1D-resistant HLA class II alleles, the INS
VNTR-mediated protection is also dominant. In mice, it dendritic cells of the peripheral immune system (Pug-
liese et al., 2001).was first shown that the promoter region of the insulin
gene drives expression of low levels of Ins message in
the thymus (Hanahan, 1998). Antigen expression under Other Genes
These data and models link the first two genes in theirthe Ins promoter in the thymus can be tolerogenic (Hana-
han, 1998), and transgenic elevation of PPI in the NOD protective action against T1D (Figure 2). Outside MHC
(IDDM1) and INS (IDDM2), with the probable exceptionthymus reduces T1D development (French et al., 1997).
The expression level, as well as the affinity for class II of the CTLA4 region on chromosome 2q33 (IDDM12)
(Nistico´ et al., 1996), no other chromosome regions inmolecules of antigens and peptides in the thymus, is a
key parameter in thymic tolerance. The level of class humans have been unequivocally linked or associated
with T1D. There is substantial evidence for other regions,II molecules themselves and the accessory molecules
involved in the interaction of the T cell receptor with including chromosomes 16q24 (Mein et al., 1998), 10p11
(IDDM10) (Mein et al., 1998), 1q24 (Concannon et al.,class II-peptide complexes also influence central dele-
tion of autoreactive T cells. It has been shown that the 1998), 6q21 (IDDM15) (Delepine et al., 1997), 6q24
(IDDM5) (Luo et al., 1996), 6q27 (IDDM8) (Luo et al.,T1D protective INS VNTR class III alleles drive higher
expression of PPI message in the human thymus (Pug- 1996), 11q13 (IDDM4) (Nakagawa et al., 1998), and 10q
(IDDM17) (Verge et al., 1998), but the case for eachliese et al., 1997; Vafiadis et al., 1997). The expression
of “peripheral” antigens in the thymus affecting T cell requires additional support. This will be forthcoming
with the improving sequence of the human genome, lessrepertoire/immune regulation is now established for sev-
eral antigens (Diez et al., 2001). This genetically regu- expensive and higher throughput DNA polymorphism
typing technology, and much larger sample sizes oflated expression of PPI in the thymus provides a model
for the mechanism of genetic protection of the INS cases, controls, and families. Larger sample sizes will
allow much more convincing statistical support for non-VNTR, with higher thymic PPI expression, increased T
cell deletion, and/or T regulatory cell production, leading HLA disease genes, in concert with analyses of func-
tional differences between alleles. The existence of mul-to increased resistance to anti-PPI responses and,
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tiple non-HLA human disease loci is strongly supported also its fine mapping. Very importantly, the conclusion
that a large number of regions contribute to T1D, andby genetic analysis of the spontaneous mouse model
of T1D, the NOD mouse, in which linkage analysis and to murine lupus, was reached following analysis of ge-
nome-wide scans for linkage has been confirmed bycongenic mapping have defined greater than 20 chro-
mosome intervals (Ikegami and Makino, 2001; Serreze congenic strain development (Ikegami and Makino,
2001; Morel et al., 2001; Serreze and Leiter, 2001; Wickerand Leiter, 2001).
The third known locus, which remains to be fully con- et al., 1995).
The orthologs of genes within a defined mouse chro-firmed and characterized, in human T1D maps, is close
to CTLA4 and may well affect its expression, or the mosome interval are strong candidates for human dis-
ease loci. Since the mapping of the human loci for manyexpression of the neighboring gene, ICOS1. The gene
products of both loci regulate T cell activity. Only one diseases, such as T1D and MS, is in its infancy owing
to small sample sizes and the lack of loci with majoramino acid variant has been found in CTLA-4 in Euro-
pean-derived populations (Yanagawa et al., 1995), and effects, mouse T1D regions provide valuable clues as
to where to look for disease genes in the human genome.this, an Ala-Thr substitution at position 49, in the leader
peptide, is unlikely to account functionally for the dis- The worth of this information is absolutely dependent
on the similarity of the model to the human disease. Theease association of the gene region (Nistico´ et al., 1996).
An extensive correlation of variants in and around CTLA4 NOD mouse is a good model for T1D particularly since
the class II gene variants, which in both disease pro-with expression of CTLA4 is required. CTLA-4 is neces-
sary, at least in mice, for the downregulation of T cells cesses are the major loci, are conserved across species,
suggesting common antigens and common immunolog-after activation, and also is constitutively expressed on
certain T regulatory cells in mice. Its gene-targeted dis- ical pathways (Cucca et al., 2001; Lee et al., 2001). Many
other aspects of disease pathogenesis in the NODruption leads to severe immune disease, depending on
the genetic background of the mouse strain. It not known model mirrors features of the human disease: the accu-
mulation of inflammatory cells in the islets, the presenceyet what effect the protective alleles of the CTLA4 region
have on CTLA-4 expression and subsequent function, of autoantibodies and autoreactive T cells, and defects
in the antigen-presenting cell compartment (Serreze andbut early studies suggest a dysregulation of T cell activ-
ity (Kouki et al., 2000). The exon 1 variant of CTLA4 was Leiter, 2001; Yu et al., 2000). There is a major gender
difference, however, with a bias in female incidence infirst associated with GD (Yanagawa et al., 1995) and has
now been associated with a number of other immune- NOD mice more akin to other endocrine autoimmune
diseases such as GD rather than T1D. T1D only showsmediated diseases (Ahmed et al., 2001), suggesting that
the etiological variant(s) close to CTLA4 does indeed a female preponderance in countries with low incidence;
otherwise, the male:female ratio exceeds 1:1 to somefunction in the regulation of T cell inflammation. This
locus, along with the MHC, provides a partial explana- degree, approaching 2:1 in cases diagnosed over age
12 years (Gale and Gillespie, 2001) and in a subset oftion why diseases such as T1D and GD cosegregate in
families. cases from certain countries, such as Sardinia, in T1D
patients positive for DR3 and negative for DR4 (Cucca
et al., 1998).Animal Models
The initial search for loci that influence disease using
linkage analysis, the correlation of phenotype with re- Fine Mapping Reveals a Multiplicity of Clustered Loci
The ability to create disease-resistant congenic strainscombination fraction between markers and disease loci
and position along chromosomes, is more feasible in has allowed us to recognize that it is relatively “easy”
to cure diabetes genetically. In addition to the MHC,animal models than in human pedigrees (Mein et al.,
1998; Todd et al., 1991). In backcrosses (or F2 crosses) regions on mouse chromosomes 1, 2, 3, 4, 6, 9, and 17
(in a region proximal to the MHC) have now been shownof the disease-sensitive and -resistant strains, both of
which are inbred, less than 500 meioses in general are by congenic strain analysis to confer significant protec-
tion from disease (Carnaud et al., 2001; Serreze andrequired to obtain convincing statistical evidence for
linkage of a chromosome region with disease. In con- Leiter, 2001). A subset of the genes analyzed in the NOD
model by reiterative congenic analysis is summarizedtrast, several thousand meioses are required in human
studies owing to their outbred nature and the relatively in Tables 1 and 2. A common theme is that multiple
genes usually account for the disease protection initiallysmaller effect of each gene (Risch, 2000). Unless the
gene effect is large, such as HLA in T1D, few multifacto- defined under a broad linkage curve (Flint and Mott,
2001; Lyons and Wicker, 1999; Morel et al., 2001; Serrezerial disease loci have been localized yet beyond reason-
able doubt, because sample sizes have been less than et al., 1998). Paradoxically, as a region is dissected to
reveal the component Idd loci and as a single Idd locus1000 meioses and studies have, thus, been statistically
underpowered to detect effects with odds ratios in the is isolated in a congenic strain, it is observed that the
locus on its own may provide minimal or no protectiontwo to three range.
Sample sizes have to be even larger to narrow the from T1D. This is the case for such loci as Idd10, Idd18,
Idd5.1, and Idd5.2 (Hill et al., 2000; Podolin et al., 1997).chromosome region to attempt fine mapping of the hu-
man disease locus. However, in rodents, the develop- Perhaps if disease loci were not found in clusters, then
the congenic approach would have failed to verify thement of congenic strains bearing disease-resistant and
-sensitive regions containing one or more genes has linkage results. Indeed, if isolated Idd loci were the norm,
in most cases the genome scans would have most likelynow been achieved by several investigators, providing
not only confirmation of the existence of the locus but failed to detect the single loci that contribute minimal
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Table 1. Disease Protection Mediated by Selected Idd Genes
% Diabetes at 7 months of
Idd gene or genes age in females Comments Reference
NOD 80%
3 25% Delay of onset of diabetes Lyons et al., 2000a
9.3 65% Delay of onset of diabetes Lyons et al., 2000b
9.2/9.3 25% Delay of onset of diabetes Lyons et al., 2000b
5.1/5.2 40% Delay of onset of diabetes Hill et al., 2000
10/18 50% Podolin et al., 1998
3/10/18 5% Most mice have no insulitis Podolin et al., 1997
9.1/9.2/9.3 3% Extensive insulitis associated with Lyons et al., 2000b
IL4 and CD30 expression
3/5.1/5.2 1% No insulitis in most mice Hill et al., 2000
10, 18, 5.1, and 5.2: Minimal or no protection when present as single Idd-resistant genes (Hill et al., 2000; Podolin et al., 1998).
protection on their own. Perhaps the clustering of loci allotypes (Podolin et al., 2000). Other candidate genes
mapped to the 0.15 cM genetic interval (780 kb) arehas a selective advantage by allowing the accumulation
of variants that function together to create a phenotype Fgf2 (Lyons et al., 2000a) and the newly described gene
encoding the T cell lymphokine IL21 (Parrish-Novak etwith survival value when exposed to a particular selec-
tive pressure. It is likely that many gene variants that al., 2000). The difficulty in defining the functional varia-
tion encoded within an Idd interval that is responsiblepositively contribute to a pro-inflammatory environment
within an autoimmune-prone individual have been main- for changing the course of disease is clearly exemplified
by the Idd3 interval. As the sequence of the Idd3 diseasetained in rodent and human populations as determinants
of natural host resistance to infectious disease. Con- interval from both strains is defined and the complete
catalog of polymorphisms found, nearly all of the hun-versely, and the theme of this review, alleles that contrib-
ute to the essential anti-inflammatory regulation of the dreds of observed variants will be irrelevant to disease
progression. Sophisticated methods of expression anal-immune response will also have been under selection.
Thus, the identification of variants underpinning autoim- ysis such as interval-specific RT-PCR Taqman or com-
plete expression profiling by “oligonucleotide tiling”mune diseases will likely identify loci that influence im-
mune, as well as autoimmune, responses at the points (Shoemaker et al., 2001) the Idd interval may be essential
to reveal variants altering expression levels or splicingof induction, expansion, and termination. NRAMP1, a
candidate for Idd5.2 and IDDM13 (Esposito et al., 1998), of mRNA (assuming that proper cell populations under
relevant conditions are assessed). However, such meth-and CTLA4, a candidate for Idd5.1 and IDDM12 (Hill et
al., 2000), provide possible molecular examples of both ods will not elucidate variants that affect regulation at
the level of translation or structural variants alteringthe conservation in etiology between the mouse and
human diseases, and the overlap between host resis- function. For example, a structural variant in an enzyme
may only alter enzyme function modestly as measuredtance to infectious disease and predisposition to inflam-
matory disease. in an in vitro assay system, but the cumulative effect of
such a variant in vivo could be sufficient to change
the progression of disease. In addition, until all of theIdd3—A Paradigm for an Idd Locus?
The most potent single Idd locus mapped to a small (1 functional activities of a gene product encoded within
the Idd interval are understood, variation in the functioncM) interval is Idd3 (Lyons et al., 2000a). A disease-
resistant allele at Idd3 reduces disease by 70% in NOD of that protein is obviously impossible to assess com-
pletely. Perhaps Idd3 is Il2, but the relevant functionalfemales and by 95% in NOD males. Although a variant
Il2 located within the Idd3 interval has been the obvious difference between the NOD and B6 allotypes has yet
to be identified and tested.candidate gene, no convincing evidence describing a
functional difference between the NOD and B6 IL2 mole- Although knockout/replacement strategies can be uti-
lized for testing particular candidate polymorphisms, thecules has been forthcoming even though there is an
obvious glycosylation difference between these two IL2 lack of NOD-derived ES cells that efficiently transmit
Table 2. Candidate Genes for Selected Idd Loci
Candidates known to
Idd Chrom cM be variant Other candidate genes Reference
3 3 0.15 Il2 Fgf2, Il21 Lyons et al., 2000a
10 3 1.6 none Nras ruled out Podolin et al., 1998
18 3 2.4 none Csf1 ruled out Podolin et al., 1998
5.1 1 1.5 Casp8 Cflar (FLIP), Cd28, Cd152, and ICOS Hill et al., 2000
5.2 1 5.1 Nramp1 Cmkar2 (CXCR2, IL8 receptor alpha) Hill et al., 2000
9.1 4 35.7 Jak1, Lck Lyons et al., 2000b
9.2 4 5.6 Tnfr2, Cd30 Lyons et al., 2000b
9.3 4 2.0 Cd137 (4-1bb) Lyons et al., 2000b
Immunity
392
to the germline hinders this approach and makes the NOD background exacerbates the thyroiditis substan-
tially (Wicker, 1997). The thyroiditis observed in theanalysis of each replacement laborious. The discovery
of a more proximal biological effect controlled by the NOD.H2h4 strain is further worsened by exposure to in-
creased levels of dietary iodine (Hutchings et al., 1999;Idd interval that in turn influences disease progression
would certainly facilitate the analysis of gene-associ- Rasooly et al., 1996). The ability of the H2g7 haplotype
to provide susceptibility to diabetes, whereas the H2h4ated variants within the interval.
haplotype increases thyroid inflammation, suggests that
specific peptide presentation, an islet-specific peptidePotent Protection from Multiple Idd Loci
for the NOD class II molecule and a thyroid-specificDespite the difficulties detailed in the section above
peptide for the H2h4 class II molecule, explains in partconcerning the identification of Idd loci, the potential
the role of class II molecules. This is in contrast to thetherapeutic gains to be realized from the understanding
hypothesis that the NOD class II molecule contributesof how these gene variants predispose to autoimmune
to autoimmunity to many tissues because of its relativelydisease are enormous. The unexpected observation that
unstable structure and promiscuous peptide bindingthe combination of a small number of resistance alleles,
(Kanagawa et al., 1998). Another potential parallel be-each on their own showing no or partial protection from
tween humans and mice predisposed to GD or thyroidi-T1D, provides nearly complete protection from disease
tis, respectively is the linkage of GD and of thyroid auto-(Table 1) emphasizes the need to decipher the pathways
antibody to the CTLA4 region (Nistico´ et al., 1996; Tomerto which the individual loci contribute. Three resistance
et al., 2001). The dependence of thyroiditis developmentallele combinations, each combination causing a pro-
on the presence of the NOD-derived Ctla4 genetic regionfound, and additive (Cordell et al., 2001) reduction in
(Idd5.1) awaits further studies.disease, have been defined: Idd3/10/18 (Podolin et al.,
The NOD mouse also has other well-characterized1997), Idd3/5.1/5.2 (Hill et al., 2000), and Idd9.1/9.2/9.3
autoimmune phenotypes, most notably the infiltration(Lyons et al., 2000b). The Idd3/10/18 and Idd3/5.1/5.2
of the salivary and lacrimal glands. This autoimmunegene combinations provide a significant reduction of
clustering is evident in many different strains of NODinsulitis in addition to disease protection (Hill et al., 2000;
congenic mice having diabetes resistance alleles intro-Podolin et al., 1997). The paucity of inflammatory cells
gressed onto the NOD background. Such strains displayin the islets suggests that these two gene combinations
a complete or partial reduction in the frequency of diabe-influence the number of T cells that escape tolerance
tes but show significant autoimmune responses to othermechanisms, either centrally in the thymus or in the
tissues. NOD congenic strains such as NOD.H2b orperiphery. In contrast, the Idd9.1/9.2/9.3 combination
NOD.B10 Idd9.1/9.2/9.3 are free or nearly free of diabe-allows the development of insulitis even though very
tes but still display significant salivary gland infiltratesfew individual animals develop clinical disease (Lyons et
and dysfunction (Brayer et al., 2000; Robinson et al.,al., 2000b). The presence of IL-4 and a lack of interferon
1998). Interestingly, the highly diabetes-protected con-within the immune cells invading the islets characterize
genic strain NOD.B6/B10 Idd3 Idd5 discussed above isthe insulitis present in mice with resistant genes at
also protected from inflammation and dysfunction of theIdd9.1/9.2/9.3. This suggests that protection from the
salivary glands (Brayer et al., 2000), suggesting that theIdd9 gene combination functions by preventing the ac-
combination of resistance genes at Idd3 and Idd5 couldcumulating self-reactive cells in the islets from evolving
potentially offer insight into a general mechanism ofinto pathogenic effector cells.
maintaining a self-tolerant, anti-inflammatory state.The characterization of the attenuation of T1D in the
Thus, the clustering of autoimmune syndromes in ex-congenic strains containing multiple resistant genes is
tended human pedigrees, which has been presumed toonly a first step in determining the level at which the
be due to the inheritance of genes that predispose to aindividual loci contribute to the profound disease pro-
reduction in self-tolerance in general, also appears totection. During immune responses in which the NOD
be an attribute of the NOD model. Interestingly, studiesparental strain and a highly protected congenic strain
with NOD congenic strains focused on a nonspontane-are compared, differences among the candidate genes
ous response, experimental autoimmune encephalomy-contained within each relevant interval should be dis-
elitis, have also suggested that Idd loci can alter suchcernible and potentially lead to the definition of the un-
an induced response (Encinas et al., 1999). Since lociderlying pathways.
that can modulate an immune response are closely
linked in many regions of the genome, declaration of aType 1 Diabetes Genes Influence More Than
colocalization of a gene that influences two differentDiabetes/Inflammatory Disease Genes
diseases requires that the analysis use congenic strainsThe clustering of organ-specific autoimmune diseases,
having finely defined genetic intervals.characterized by the accumulation of inflammatory cells
in the target organ, that is observed in families of T1D
probands is also observed in the animal models of dia- Therapeutic Implications
How shall the identification of loci that alter the develop-betes, the NOD mouse, and the BB rat. Both rodent
species are noted for their development of autoimmune ment of diabetes and other inflammatory diseases influ-
ence the development of treatments to prevent the onsetthyroiditis (Delemarre et al., 1996; Rose et al., 1997). A
suggestion that a key autoantigen may be driving thyroid of T1D or reverse the progression of disease? As de-
tailed in this review, the identification of these loci willdisease on the NOD background is that although minor
infiltrates are seen in the thyroid glands of NOD mice in continue to be slow and difficult. However, the observa-
tion that a relatively small number of disease-resistantsome colonies, introgression of the H2h4 MHC onto the
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tions in a complex disease. Rejection of the multiplicative model ofloci can almost completely prevent T1D in the NOD
epistasis in type 1 diabetes. Genetics 158, 357–367.mouse model emphasizes that a relatively subtle thera-
Cucca, F., Goy, J.V., Kawaguchi, Y., Esposito, L., Merriman, M.E.,peutic intervention could profoundly reduce disease
Wilson, A.J., Cordell, H.J., Bain, S.C., and Todd, J.A. (1998). A male-progression. The more T1D loci that are identified, the
female bias in type 1 diabetes and linkage to chromosome Xp in
greater the chances are of finding one or more targets MHC HLA-DR3-positive patients. Nat. Genet. 19, 301–302.
that are approachable by gene therapy, antisense tech-
Cucca, F., Lampis, R., Congia, M., Angius, E., Nutland, S., Bain, S.,
nology, protein therapy, or chemicals. Unfortunately, Barnett, A., and Todd, J. (2001). A correlation between the relative
many potential targets will have to be set aside until predisposition of MHC class II alleles to type 1 diabetes and the
technical advancements in therapeutic modalities are structure of their proteins. Hum. Mol. Genet., in press.
made. For example, large protein-protein interactions Delemarre, F.G., Simons, P.J., and Drexhage, H.A. (1996). The BB
rat as a model for autoimmune thyroiditis: relevance for the patho-such as those found in many receptor-ligand interac-
genesis of human disease. Exp. Clin. Endocrinol. Diabetes 104tions (such as IL2, interferon , and TNF  for their
(Suppl 3), 10–12.respective receptors) are tractable only with blocking
Delepine, M., Pociot, F., Habita, C., Hashimoto, L., Froguel, P., Rot-or neutralizing biologics rather than a small molecule
ter, J., Cambon-Thomsen, A., Deschamps, I., Djoulah, S., Weissen-drug.
bach, J., et al. (1997). Evidence of a non-MHC susceptibility locus
The goal, therefore, is to dissect the biologic pathways in type 1 diabetes linked to HLA on chromosome 6. Am. J. Hum.
that contribute to autoimmune disease “from the genes Genet. 60, 174–187.
out” and to use that knowledge to slow or even reverse Diez, J., Park, Y., Zeller, M., Brown, D., Garza, D., Ricordi, C., Hutton,
the destruction of self. The tantalizing clues provided J., Eisenbarth, G., and Pugliese, A. (2001). Differential splicing of
the IA-2 mRNA in pancreas and lymphoid organs as a permissiveby the profound genetically mediated disease protection
genetic mechanism for autoimmunity against the IA-2 type 1 diabe-afforded by the combination of just two or three resis-
tes autoantigen. Diabetes 50, 895–900.tance genes confirms that the goal is achievable. The
Encinas, J.A., Wicker, L.S., Peterson, L.B., Mukasa, A., Teuscher,evidence also suggests that combination therapy, one
C., Sobel, R., Weiner, H.L., Seidman, C.E., Seidman, J.G., and Kuch-in which two or more critical pathways leading to a
roo, V.K. (1999). QTL influencing autoimmune diabetes and enceph-
lack of tolerance are altered by therapeutic intervention, alomyelitis map to a 0.15-cM region containing Il2. Nat. Genet. 21,
could hold the most promise. 158–160.
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